Table 2—

Prospective studies of OHA for type 2 diabetic patients using electronic monitoring

ReferencenPopulationAge (years)MedicationsFollow-upHbA1cAdherence rateDose interval*
Mason et al. (26)21ClinicSulfonylurea3 months>8%74.5%
Matsuyama et al. (27)15Intervention84 ± 8OHA3 months12.7 ± 1.985.1%
17Control12.1 ± 2.682.8%
Paes et al. (28)91Community69OHA6 months67.2 ± 30%
(40 o.d.)79.1 ± 19%77.7 ± 21%
(36 b.i.d.)65.6 ± 30%40.7 ± 28%
(15 t.i.d.)38.1 ± 36%5.3 ± 5%
Rosen et al. (29)77Clinic65Metformin4 weeks7.9 ± 1.177.7 ± 18%
Rosen et al. (30)16Intervention63 ± 11Metformin6 months79.3 ± 13%
17Control60.7 ± 13%
  • *

    * Dose interval = proportion of dose taken within the prescribed number of hours between doses (e.g., b.i.d. = 12 ± 6–h interval).